Relapse-free survival as a surrogate for overall survival in the evaluation of stage II-III melanoma adjuvant therapy.
dc.contributor.author | Suciu, S | |
dc.contributor.author | Eggermont, A | |
dc.contributor.author | Lorigan, Paul C | |
dc.contributor.author | Kirkwood, J | |
dc.contributor.author | Markovic, S | |
dc.contributor.author | Garbe, C | |
dc.contributor.author | Cameron, D | |
dc.contributor.author | Kotapati, S | |
dc.contributor.author | Chen, T | |
dc.contributor.author | Wheatley, K | |
dc.contributor.author | Ives, N | |
dc.contributor.author | de Schaetzen, G | |
dc.contributor.author | Efendi, A | |
dc.contributor.author | Buyse, M | |
dc.date.accessioned | 2017-10-23T19:56:24Z | |
dc.date.available | 2017-10-23T19:56:24Z | |
dc.date.issued | 2018-01-01 | |
dc.identifier.citation | Relapse-free survival as a surrogate for overall survival in the evaluation of stage II-III melanoma adjuvant therapy. 2018, 110 (1): J Natl Cancer Inst | en |
dc.identifier.issn | 1460-2105 | |
dc.identifier.pmid | 28922786 | |
dc.identifier.doi | 10.1093/jnci/djx133 | |
dc.identifier.uri | http://hdl.handle.net/10541/620624 | |
dc.description.abstract | We assessed whether relapse-free survival (RFS; time until recurrence/death) is a valid surrogate for overall survival (OS) among resected stage II-III melanoma patients through a meta-analysis of randomized controlled trials. | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to Journal of the National Cancer Institute | en |
dc.subject.mesh | Antibodies, Monoclonal | |
dc.subject.mesh | Antineoplastic Agents | |
dc.subject.mesh | Chemotherapy, Adjuvant | |
dc.subject.mesh | Disease-Free Survival | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Interferon-alpha | |
dc.subject.mesh | Melanoma | |
dc.subject.mesh | Neoplasm Staging | |
dc.subject.mesh | Randomized Controlled Trials as Topic | |
dc.subject.mesh | Skin Neoplasms | |
dc.subject.mesh | Survival Rate | |
dc.title | Relapse-free survival as a surrogate for overall survival in the evaluation of stage II-III melanoma adjuvant therapy. | en |
dc.type | Article | en |
dc.contributor.department | European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium | en |
dc.identifier.journal | Journal of the National Cancer Institute | en |
refterms.dateFOA | 2018-12-17T15:08:49Z | |
html.description.abstract | We assessed whether relapse-free survival (RFS; time until recurrence/death) is a valid surrogate for overall survival (OS) among resected stage II-III melanoma patients through a meta-analysis of randomized controlled trials. |